Assignee profile:

Ipsen Biopharm Ltd.

City:

Wrexham

Country:

United Kingdom

Published Applications:

35

Last publication date:

2026-01-01

Patent Grants:

15

Last grant date:

2025-07-22

Top Inventors for applications by Ipsen Biopharm Ltd.

These are the the leading inventors for applications assigned to Ipsen Biopharm Ltd.:

Recent patent applications by Ipsen Biopharm Ltd.

Ipsen Biopharm Ltd. based in Wrexham, GB has been assigned the rights to these inventions. The list includes both Pending Applications and Patent Grants:

#1 | 2026-01-01
US20260000666A1
Human necessities

Methods For Treating Pancreatic Cancer Using Combination Therapies

#2 | 2025-12-18
US20250381191A1
Human necessities

Methods for Treating Metastatic Pancreatic Cancer Using Combination Therapies Comprising Liposomal Irinotecan and Oxaliplatin

#3 | 2025-05-15
US20250152578A1
Human necessities

Stabilizing Camptothecin Pharmaceutical Compositions

#4 | 2025-01-02
US20250000796A1
Human necessities

Stabilizing Camptothecin Pharmaceutical Compositions

#5 | 2024-10-31
US20240358706A1
Human necessities

Methods for Treating Metastatic Pancreatic Cancer Using Combination Therapies Comprising Liposomal Irinotecan and Oxaliplatin

#6 | 2024-10-17
US20240342162A1
Human necessities

Methods For Treating Pancreatic Cancer Using Combination Therapies

#7 | 2024-07-11
US20240226090A1
Human necessities

Methods For Treating Pancreatic Cancer Using Combination Therapies Comprising Liposomal Irinotecan

#8 | 2023-06-15
US20230181567A1
Human necessities

Liposomes Useful for Drug Delivery

#9 | 2023-04-06
US20230108934A1
Human necessities

Stabilizing Camptothecin Pharmaceutical Compositions

#10 | 2023-03-23 ✅ Patent 12,364,691 granted on 2025-07-22
US20230088999A1
Human necessities

Methods For Treating Pancreatic Cancer Using Combination Therapies

#11 | 2023-03-09 ✅ Patent 11,844,795 granted on 2023-12-19
US20230074866A1
Human necessities

Combination therapy for cancer treatment

#12 | 2023-03-02
US20230062425A1
Human necessities

Methods for Treating Metastatic Pancreatic Cancer Using Combination Therapies Comprising Liposomal Irinotecan and Oxaliplatin

#13 | 2023-01-05
US20230000858A1
Human necessities

Nanoliposomal Irinotecan for Use in Treating Small Cell Lung Cancer

#14 | 2022-03-31
US20220096458A1
Human necessities

Methods For Treating Pancreatic Cancer Using Combination Therapies Comprising Liposomal Irinotecan

#15 | 2021-07-29
US20210228567A1
Human necessities

Stabilizing Camptothecin Pharmaceutical Compositions

#16 | 2021-07-08 ✅ Patent 12,059,497 granted on 2024-08-13
US20210205219A1
Human necessities

Stabilizing camptothecin pharmaceutical compositions

#17 | 2021-06-03 ✅ Patent 12,060,553 granted on 2024-08-13
US20210163924A1
Chemistry; metallurgy

Evolution of BoNT peptidases

#18 | 2021-05-13
US20210137914A1
Human necessities

Liposomes Useful for Drug Delivery

#19 | 2020-11-19
US20200360367A1
Human necessities

Treatment of Breast Cancer with Liposomal Irinotecan

#20 | 2020-08-27
US20200268742A1
Human necessities

Combination Therapy for Cancer Treatment

#21 | 2020-06-11
US20200179371A1
Human necessities

Stabilizing Camptothecin Pharmaceutical Compositions

#22 | 2020-03-05 ✅ Patent 10,993,914 granted on 2021-05-04
US20200069586A1
Human necessities

Stabilizing camptothecin pharmaceutical compositions

#23 | 2020-01-30 ✅ Patent 11,071,726 granted on 2021-07-27
US20200030302A1
Human necessities

Treating gastric cancer using combination therapies comprising liposomal irinotecan, oxaliplatin, 5-fluorouracil (and leucovorin)

#24 | 2019-08-29
US20190262331A9
Human necessities

Stabilizing Camptothecin Pharmaceutical Compositions

#25 | 2019-06-06 ✅ Patent 11,318,131 granted on 2022-05-03
US20190167661A1
Human necessities

Nanoliposomal irinotecan for use in treating small cell lung cancer

#26 | 2019-05-16
US20190142822A1
Human necessities

Treatment of Breast Cancer with Liposomal Irinotecan

#27 | 2019-04-25 ✅ Patent 11,369,597 granted on 2022-06-28
US20190117644A1
Human necessities

Methods for treating pancreatic cancer using combination therapies

#28 | 2019-04-25 ✅ Patent 10,744,130 granted on 2020-08-18
US20190117643A1
Human necessities

Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan

#29 | 2019-04-11
US20190105317A1
Human necessities

Stabilizing Camptothecin Pharmaceutical Compositions

#30 | 2018-10-18 ✅ Patent 10,456,360 granted on 2019-10-29
US20180296484A1
Human necessities

Stabilizing camptothecin pharmaceutical compositions

#31 | 2017-02-09 ✅ Patent 9,737,528 granted on 2017-08-22
US20170035749A1
Human necessities

Liposomes useful for drug delivery to the brain

#32 | 2016-12-29 ✅ Patent 9,717,724 granted on 2017-08-01
US20160375004A1
Human necessities

Methods for treating pancreatic cancer using combination therapies

#33 | 2016-04-07 ✅ Patent 9,724,303 granted on 2017-08-08
US20160095817A1
Human necessities

Liposomes useful for drug delivery

#34 | 2016-02-04 ✅ Patent 9,730,891 granted on 2017-08-15
US20160030341A1
Human necessities

Liposomes useful for drug delivery

#35 | 2015-07-02 ✅ Patent 9,717,723 granted on 2017-08-01
US20150182460A1
Human necessities

Liposomes useful for drug delivery

Also check out Ipsen Biopharm Ltd.'s (Wrexham, United Kingdom) applicant profile with 30 patent applications submitted.

AssigneeID:

140615 ⎘